Core Insights - Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2025, with a 3% decline in revenue on both reported and ex-FX basis, although the biosimilar franchise performed better than expected, particularly driven by HADLIMA [2][3][4] Revenue and Financial Performance - The company guided for approximately $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2026, indicating a stable outlook compared to 2025 [3][20] - Adjusted gross margin is expected to decline by about 75–100 basis points in 2026, primarily due to higher cost of goods sold [21] - Organon reported a Q4 2025 net loss of $205 million, influenced by a $301 million goodwill impairment, while non-GAAP adjusted net income was $165 million for Q4 and $954 million for the full year [16][17] Biosimilars and Product Performance - The biosimilars segment, particularly HADLIMA, grew approximately 61% ex-FX in 2025, with expectations for flat to modest growth in 2026 [4][11][12] - The company launched a denosumab biosimilar in the U.S. in late September 2025, contributing to the biosimilars growth [11] - Nexplanon received FDA approval to extend its duration from three to five years, but management anticipates a volume headwind due to policy-driven access changes and a shift in reinsertions [5][9][10] Strategic Focus and Outlook - Organon aims to stabilize revenue, maintain profitability, and continue deleveraging, with a target of net leverage below 4.0x by the end of 2026 [3][18] - The company plans to reduce its dividend payout ratio to support debt reduction and has divested the JADA System, generating approximately $390 million in net proceeds [18][20] - Management expects interest expense of about $500 million and depreciation of about $140 million for 2026, with a non-GAAP tax rate projected between 27.5% and 29.5% [22]

Financial Data and Key Metrics Changes - In 2025, Organon reported $6.2 billion in revenue and $1.9 billion of adjusted EBITDA, representing a 3% decline on both a reported and ex-FX basis [6] - Adjusted gross margin for Q4 2025 was 56.7%, down from 60.6% in Q4 2024, primarily due to pricing pressure and unfavorable product mix [22] - Net loss for Q4 2025 was $205 million, or $0.79 per diluted share, compared to net income of $109 million, or $0.42 per diluted share in Q4 2024 [23] Business Line Data and Key Metrics Changes - Women's health revenue decreased 16% ex-FX in Q4 and 2% for the year, with Nexplanon sales down 20% ex-FX in Q4 and 4% for the full year [11] - The fertility business declined 6% ex-FX in Q4 2025 but grew 8% ex-FX for the full year, driven by performance in the U.S. [14] - Biosimilars revenue was driven by HADLIMA, which grew 61% ex-FX globally for the full year [16] Market Data and Key Metrics Changes - Nexplanon faced challenges due to government policy-related access restrictions impacting its market share in the U.S. [12] - The JADA System generated $74 million in revenue in 2025 before its divestiture, which will impact consolidated revenue in 2026 [15] - The company expects strong growth in Latin America for Nexplanon, offsetting U.S. declines [14] Company Strategy and Development Direction - Organon decided to lower its dividend payout ratio to focus on debt reduction and improve its balance sheet capacity for future growth opportunities [7] - The company is scrutinizing spending and has discontinued early-stage clinical programs to focus on products already in the market [9] - For 2026, Organon expects to maintain revenue and adjusted EBITDA in line with 2025, targeting approximately $6.2 billion in revenue and $1.9 billion in adjusted EBITDA [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2026 targets despite anticipated gross margin deterioration and ongoing operational challenges [10] - The company is committed to managing operating expenses and capital deployment to support deleveraging efforts [32] - Management highlighted the importance of maintaining performance aligned with the previous year while navigating a competitive landscape [32] Other Important Information - The company divested the JADA System, resulting in approximately $390 million in net proceeds to reduce net debt in 2026 [8] - Organon expects to achieve net leverage below 4x by the end of 2026, supported by debt repayments and revenue from the JADA divestiture [27] Q&A Session Summary Question: Concerns about channel behavior issues and audit committee investigation scope - Management could not provide additional details regarding the audit committee's findings beyond what was previously disclosed [36] Question: Status of FDA draft guidance on biosimilars and its impact - Management views the FDA guidance as incremental and believes their current biosimilar strategy is appropriate for future growth [40] Question: Nexplanon contribution to 2026 sales guidance - Nexplanon is expected to be roughly flat year-on-year, with growth anticipated outside the U.S. but a dip in the U.S. due to the transition to a five-year label [41] Question: Operating costs and margins outlook - Management emphasized the need to streamline operations while ensuring that cost reductions do not hinder revenue growth opportunities [51] Question: Pressure on established brands and competitive dynamics for Vtama - Management expects established brands to stabilize but acknowledges potential challenges, particularly in the respiratory segment [58]